Veriti Management LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 5.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 15,096 shares of the biopharmaceutical company’s stock after buying an additional 783 shares during the quarter. Veriti Management LLC’s holdings in Gilead Sciences were worth $897,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Norges Bank acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $950,911,000. Capital World Investors grew its holdings in shares of Gilead Sciences by 15.4% during the 4th quarter. Capital World Investors now owns 42,681,624 shares of the biopharmaceutical company’s stock worth $3,099,157,000 after purchasing an additional 5,705,315 shares in the last quarter. EP Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 72,909.8% during the 3rd quarter. EP Wealth Advisors LLC now owns 3,613,253 shares of the biopharmaceutical company’s stock worth $322,000 after purchasing an additional 3,608,304 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Gilead Sciences by 65.1% during the 4th quarter. Renaissance Technologies LLC now owns 9,082,069 shares of the biopharmaceutical company’s stock worth $659,449,000 after purchasing an additional 3,581,114 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of Gilead Sciences by 4.0% during the 4th quarter. State Street Corp now owns 57,369,269 shares of the biopharmaceutical company’s stock worth $4,165,583,000 after purchasing an additional 2,187,144 shares in the last quarter. 80.16% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Gilead Sciences stock opened at $61.51 on Thursday. The company has a quick ratio of 1.30, a current ratio of 1.48 and a debt-to-equity ratio of 1.31. Gilead Sciences, Inc. has a 12 month low of $57.17 and a 12 month high of $74.12. The business has a fifty day simple moving average of $61.98 and a 200 day simple moving average of $64.15. The stock has a market cap of $77.15 billion, a PE ratio of 17.18, a price-to-earnings-growth ratio of 0.59 and a beta of 0.37.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 29th. Shareholders of record on Wednesday, June 15th will be paid a $0.73 dividend. The ex-dividend date is Tuesday, June 14th. This represents a $2.92 dividend on an annualized basis and a yield of 4.75%. Gilead Sciences’s payout ratio is 81.56%.
Several analysts have recently weighed in on the company. Barclays decreased their price objective on Gilead Sciences from $63.00 to $56.00 and set an “underweight” rating on the stock in a report on Thursday, March 10th. Wells Fargo & Company cut their target price on Gilead Sciences from $70.00 to $63.00 and set an “equal weight” rating for the company in a research report on Tuesday, March 22nd. Morgan Stanley cut their target price on Gilead Sciences from $69.00 to $63.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 12th. SVB Leerink started coverage on Gilead Sciences in a research report on Monday, May 23rd. They set a “market perform” rating and a $68.00 target price for the company. Finally, BMO Capital Markets started coverage on Gilead Sciences in a research report on Tuesday, June 7th. They set a “hold” rating and a $63.00 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Hold” and an average target price of $72.07.
Gilead Sciences Company Profile (Get Rating)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.
- Get a free copy of the StockNews.com research report on Gilead Sciences (GILD)
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Victoria’s Secret Stock is Out of the Box
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.